|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-2.71/--
|
企业价值
15.08M
|
资产负债 |
每股账面净值
1.28
|
现金流量 |
现金流量率
--
|
损益表 |
收益
122.11K
|
每股收益
0.20
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2025/01/21 05:40 EST
同行比较之报价最少15分钟延迟
业务概览
|
|||
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, andtelehealth-friendly POCTs powered by the AI Nose technology platform. |